Furthermore, adenoviral-based cancer therapy comprises the selective delivery of a therapeutic gene by adenovirus vectors to EPH/ephrin-expressing BC cells, whereas selected natural compounds target EPH/ephrin upstream positive regulators. The gene discussed is EPHA1; the disease is cancer.